Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake
In separate regulatory filings last week, Adaptive Biotechnologies Corp.
Adaptive Biotechnologies Corp (ADPT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 29,993,708 | $448,705,872 | 1.17% | |
| 2. | ARK Investment Management Catherine D. Wood | 3,165,636 | $47,357,912 | -22% | 0.28% |
| 3. | Driehaus Capital Richard Driehaus | 3,019,940 | $45,178,302 | +25% | 0.32% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,441,402 | $36,523,374 | +544% | 0.02% |
| 5. | Iron Triangle Partners Kevin Molloy | 1,820,915 | $27,240,888 | +22% | 3.87% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 2,500 | $50,000.00 | 2,500 | 2019-07-01 | Filing | |
| $20.00 | 1,000 | $20,000.00 | 1,000 | 2019-07-01 | Filing | |
| $20.00 | 300 | $6,000.00 | 300 | 2019-07-01 | Filing | |
| $20.00 | 400 | $8,000.00 | 400 | 2019-07-01 | Filing | |
| $20.00 | 500 | $10,000.00 | 500 | 2019-07-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 22,968 | $367,488.00 | 46,722 | 2025-12-10 | Filing | |
| $16.85 | 12,604 | $212,377.40 | 296,791 | 2025-12-04 | Filing | |
| $16.61 | 10,000 | $166,100.00 | 1,232,312 | 2025-12-04 | Filing | |
| $18.61 | 27,212 | $506,415.32 | 1,242,312 | 2025-12-03 | Filing | |
| $19.50 | 162,820 | $3,174,990.00 | 216,637 | 2025-11-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,357,977 | $199,835,344 | 0% | |
| 2. | 11,275,169 | $168,676,528 | 0% | |
| 3. | 5,971,706 | $89,336,731 | 0.02% | |
| 4. | 3,650,646 | $54,650,171 | 0.53% | |
| 5. | 3,650,646 | $54,613,664 | 0.03% |
News See All
Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why
Among others, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) said it expects its pharmaceutical services to generate $20 million in revenues, and anticipates EMR integrated testing volumes to exceed...
Continued Momentum Lifted Adaptive Biotechnologies Corporation (ADPT) in Q3
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor letter. The letter highlighted the market review, quarterly performance, and...
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Third Quarter Earnings Conference Call.
Adaptive Biotechnologies (ADPT) Poised for $33.7M Windfall on Genentech Deal Termination
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the must-buy small-cap stocks to invest in.
10 Must-Buy Small-Cap Stocks to Invest In
Large-cap tech giants have been the catalyst behind the US equity market rallying to record highs.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter 2025 Financial Results Conference Call.
Adaptive Biotechnologies Corporation (ADPT) Rose on Solid Results
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S.
Craig-Hallum Initiates Coverage of Adaptive Biotechnologies (ADPT) stock, Gives Buy
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers.
10 Worst Aggressive Growth Stocks to Buy According to Short Sellers
According to Morningstar, stocks have experienced a healthy recovery over the past few months. However, the momentum was insufficient to propel the market to a new high for the year.
Hedge Fund Resource Center Billionaire Hedge Funds
